180 Life Sciences Corp. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stockholders??? Equity (Deficit) (Details)

Stockholders’ Equity (Deficit) (Details) - USD ($)				1 Months Ended				3 Months Ended		9 Months Ended		12 Months Ended
Stockholders’ Equity (Deficit) (Details) - USD ($)	Jun. 22, 2028	Oct. 23, 2023	Apr. 05, 2023	Aug. 31, 2023	Apr. 30, 2023	Dec. 31, 2022	Jun. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Aug. 09, 2023	Dec. 15, 2022
Stockholders’ Equity (Deficit) (Details) [Line Items]
Par value per share (in Dollars per share)						$ 0.0001		$ 0.0001		$ 0.0001		$ 0.0001		$ 0.0001
Stock issued during period, shares, purchase of assets (in Shares)			400,000
Aggregate shares (in Shares)			1,170,680
Warrants purchase price (in Dollars per share)					$ 1.78
Company’s outstanding common stock percent				9.99%	9.99%
Warrants exercisable years				5 years	5 years 6 months
Prefunded Warrant Exercised					$ 117
Assess change in relative fair value, description										To assess for the change in relative fair value, the Company performed a Black Scholes Option Model calculation to quantify the fair value of the common warrants under their original terms as of the modification date using the following assumptions: a share price of $1.43, exercise prices of $21.20 and $3.50 for the July 2022 common warrants and December 2022 common warrants, respectively, an expected term of 4.8 and 5.2 years, respectively, volatility of 106%, a dividend rate of 0% and a discount rate of 3.36. The Company then performed a Black Scholes Option Model calculation to quantify the fair value of the common warrants with their new modified terms as of the modification date using the following assumptions: a share price of $1.43, an exercise price of $1.78 for both the July 2022 common warrants and December 2022 common warrants, an expected term of 5.5 years, volatility of 106%, a dividend rate of 0% and a discount rate of 3.36. The aggregate difference of approximately $0.8 million between the two calculated amounts was recorded as an equity issuance cost within equity during the period to account for the change in relative fair value.
Shares issued (in Shares)								470,000		470,000
Aggregate shares of common stock (in Shares)													666,925
Warrants shares purchase (in Shares)								3,948,460		3,948,460
Common stock warrants purchase (in Shares)								4,615,385		4,615,385
Warrant price per share (in Dollars per share)										$ 0.65
Aggregate gross proceeds				$ 3,000,000
Warrants exercise price (in Shares)				0.0001
Warrants purchased					$ 306,604	$ 2,571,429	$ 1,570,680
Exercise price per share (in Dollars per share)													$ 1.78
Exercise price (in Dollars per share)								$ 1.78		1.78
Share price (in Dollars per share)								$ 0.84		$ 0.84
Expected term										5 years 2 months 4 days
Volatility percentage										100.00%
Dividend rate										0.00%		0.00%
Discount rate										4.12%
Change in relative fair value								$ 1,400,000		$ 1,400,000
Vested shares issued (in Shares)								90,485
Issuance of fair value								$ 60,624
Restricted Stock (in Shares)								3,645
Amortization of restricted stock shares									$ 6,075		$ 20,250
Compensation expense								$ 672,083		2,273,947
Issuance of directors services								60,624		583,994
Amortization of restricted stock										1,692,725
General and administrative expenses								563,361		1,504,768
Research and development expenses								$ 87,846		$ 314,028
Weighted average remaining vesting period										1 year 5 months 23 days
First Amendment to the 2022 Omnibus Incentive Plan (“OIP”) [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Shares issued (in Shares)								120,000		120,000
Warrants [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Prefunded Warrant Exercised										$ 66
Pre-funded warrants (in Shares)										3,285,000
Common Warrant Agreements [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Exercise price (in Dollars per share)													$ 0.83
Black Scholes Option Model [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Exercise price (in Dollars per share)								$ 0.83		$ 0.83
Share price (in Dollars per share)								$ 0.84		$ 0.84
Expected term										5 years 2 months 4 days
Volatility percentage										100.00%
Dividend rate										0.00%
Discount rate										4.12%
Stock Options [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Compensation expense								$ 644,618		$ 1,753,349
Research and development expenses								81,257		248,581
Unrecognized stock-based compensation expense										1,993,409
Restricted Stock [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Unrecognized stock-based compensation expense										$ 2,430
Weighted average remaining vesting period										3 months
Subsequent Event [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Prefunded Warrant Exercised		$ 74
Pre-Funded Warrant Shares (in Shares)		737,000
Pre-funded warrants (in Shares)		2,548,000
General and Administrative Expense [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
General and administrative expenses								$ 584,237		$ 1,959,919
Pre-Funded Warrants (Member)
Stockholders’ Equity (Deficit) (Details) [Line Items]
Aggregate shares (in Shares)			1,570,680
Warrants purchase price (in Dollars per share)			$ 1.91
Aggregate gross proceeds			$ 3,000,000
Warrants purchase (in Shares)										1,170,680
Pre-Funded Warrant Shares (in Shares)										663,460
Warrant Price [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Warrants purchase price (in Dollars per share)	$ 3.5				$ 0.0001					$ 1.78		$ 21.2
Warrant to Purchase Common Stock [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Warrants purchase (in Shares)										306,604		2,571,429
August 2023 Offering pre-funded warrants [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Company’s outstanding common stock percent				4.99%
Exercise price per share (in Dollars per share)				$ 0.65
Restricted Stock [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Restricted Stock (in Shares)										15,390
Issuance of directors services										$ 60,624
Common Warrant [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Company’s outstanding common stock percent					9.99%